KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Net Cash Flow (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Net Cash Flow data on record, last reported at $132.7 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 121.11% year-over-year to $132.7 million; the TTM value through Dec 2025 reached $424.7 million, up 107.38%, while the annual FY2025 figure was $424.7 million, 107.38% up from the prior year.
  • Net Cash Flow reached $132.7 million in Q4 2025 per VRTX's latest filing, up from -$30.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $1.3 billion in Q4 2022 and bottomed at -$4.6 billion in Q2 2024.
  • Average Net Cash Flow over 5 years is -$46.7 million, with a median of $228.5 million recorded in 2021.
  • Peak YoY movement for Net Cash Flow: soared 558.1% in 2022, then tumbled 639.74% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $524.8 million in 2021, then skyrocketed by 146.61% to $1.3 billion in 2022, then tumbled by 159.63% to -$771.7 million in 2023, then rose by 18.54% to -$628.6 million in 2024, then soared by 121.11% to $132.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were $132.7 million in Q4 2025, -$30.1 million in Q3 2025, and $239.4 million in Q2 2025.